Details

Autor(en) / Beteiligte

• SINGH, Richa
• MARSHALL, Neal
• LIPMAN, Marc C
• SMITH, Colette J
• REYNOLDS, Carl J
• BREEN, Ronan A
• BHAGANI, Sanjay
• CROPLEY, Ian
• HOPKINS, Susan
• SWADEN, Leonie
• JOHNSON, Margaret A

Titel

No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients

Ist Teil von

• AIDS (London), 2013-01, Vol.27 (3), p.481-484

Ort / Verlag

Hagerstown, MD: Lippincott Williams & Wilkins

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.